E
ENTA icon

Ergoteles’s Enanta Pharmaceuticals ENTA Stock Holding History

Ergoteles’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,262
Closed -$900K – 1159
2023
Q1 		$900K Buy
22,262
+10,386
+87% +$496K 0.04% 538
2022
Q4 		$552K Buy
+11,876
New +$541K 0.02% 662
2022
Q2 		– Sell
-9,809
Closed -$698K – 1737
2022
Q1 		$698K Sell
9,809
-1,339
-12% -$87.1K 0.03% 547
2021
Q4 		$834K Buy
+11,148
New +$875K 0.03% 473
2021
Q2 		– Sell
-11,400
Closed -$562K – 1543
2021
Q1 		$562K Buy
+11,400
New +$569K 0.02% 465

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles's ENTA Position: Q2 2023 in Review

Ergoteles sold out of Enanta Pharmaceuticals (ENTA) in Q2 2023, closing a stake of 22,262 shares — an estimated $900K sold.

Ergoteles first reported a position in ENTA in Q1 2021 and held it in 5 quarters. The position peaked at $900K in Q1 2023. 133 funds tracked by Wall St. Rank hold ENTA as of Q2 2023.

  • Ergoteles reported no remaining Enanta Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 22,262 Enanta Pharmaceuticals shares in Q2 2023, an estimated $900K.
  • Ergoteles first reported a position in Enanta Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Ergoteles's Enanta Pharmaceuticals position peaked at $900K in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.